Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
June 12, 2024 16:00 ET | Acri Capital Acquisition Corporation
Austin, Texas, June 12, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
Nurix.png
Nurix Therapeutics Announces Board Chair Transition
May 20, 2024 16:00 ET | Nurix Therapeutics, Inc.
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO,...
Acri Capital Acquisition Corporation Announces Confidential Submission of Draft Registration Statement on Form S-4 and Extension of the Deadline for an Initial Business Combination
April 10, 2024 16:30 ET | Acri Capital Acquisition Corporation
Austin, Texas, April 10, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in relation to its...
Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
March 13, 2024 16:05 ET | Acri Capital Acquisition Corporation
Austin, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
ContraFect_LOGO_Web.jpg
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
October 16, 2023 07:30 ET | ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
22157.jpg
Global Antibiotic Resistance Markets, 2023-2027: Beyond Antibiotics - Exploring Cutting-Edge Trends in AMR Solutions
October 05, 2023 06:43 ET | Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
September 19, 2023 08:30 ET | ContraFect Corporation
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Press-Page - 2
41% of U.S. Workers Say They are Most Productive Outside of 9-5 Work Hours, According to Research from Fiverr
September 19, 2023 08:00 ET | Fiverr International Ltd.
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fiverr International Ltd. (NYSE: FVRR), the company that is revolutionizing how the world works together, has compiled findings from a study exploring...
ContraFect_LOGO_Web.jpg
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
September 18, 2023 07:30 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...